Peptidomimetics and metalloprotease inhibitors as anticancer drugs

• 来源期刊: 中国科学B辑（英文版）
• 年，卷（期）: 2009,（5）
• 页码范围: 535-548
• 页数: 14页
• 语种: 英文
• DOI: 10.1007/s11426-009-0040-O

摘要

Peptidomimetics with three types, as the structural or functional mimetica of natural active peptides, can preserve the bioactivity and improve the bioavailability and the specificity towards the targets of the lead peptides. Peptidomimetica of high bioectivity can be designed through various ways including conformation restriction, modification and non-peptide design. Recently the concentration on the de-velopment of cancer chemotherapeutic drugs was transferred from cytotoxic drugs to target-baeed drugs, and many proteasee and peptidases that play key roles in the process of tumor genesis and development was discovered, which means that peptidomimetice as potential cancer chemotherapeu-tic drugs should be paid close attention to. Our laboratory has focused on the development of small-molecule peplldomimetic inhibitora of APN, MMPs and HDACs as target-based anticancer agents. These three zinc-dependent metalloproteinaees play very important roles in the process of tumor genesis, invasion, metastasis, angiogenesis and matrix degradation, so small-molecule peptidomimetic inhibitora based on them would be quite potential in the development of chemotherapeutic drugs with high selectivity.